Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
Autonomix Medical (NASDAQ: AMIX) has entered a definitive agreement with RF Innovations to license the intellectual property of the FDA-cleared Apex 6 Radiofrequency Generator. This ablation technology is designed to lesion neural tissue for pain management in the peripheral nervous system. The transaction, valued at 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license. Autonomix plans to utilize this technology in its strategic therapeutic areas, potentially simplifying its regulatory strategy. The company is initially developing its technology to address pancreatic cancer-related pain, with plans for follow-on indications. This agreement is expected to accelerate Autonomix's journey in revolutionizing the diagnosis and treatment of diseases involving the nervous system.
- Acquisition of FDA-cleared ablation technology license
- Potential simplification of regulatory strategy
- Royalty-free and perpetual license agreement
- Immediate access to manufacturing partner
- Acceleration of product development and commercialization
- Dilution of existing shareholders due to 250,000 shares issuance
Insights
The definitive agreement to license the Apex 6 Generator could be financially beneficial for Autonomix. The transaction, priced at
Moreover, integrating RF Innovations’ manufacturing partner into the supply chain could improve production efficiency and scalability. From a financial standpoint, this move seems to mitigate risks, ensuring a smoother pathway to revenue generation once the product is commercialized. Investors might find this development favorable in the short-term, due to potential cost savings and the accelerated timeline to market.
However, it is important to note that the full financial impact will depend on the success of the initial development stage and subsequent market acceptance, especially in managing pancreatic cancer-related pain, a market segment where current solutions are limited.
The inclusion of the Apex 6 Generator into Autonomix’s technology platform is a significant development from a medical research perspective. The generator’s existing FDA clearance for pain management in the peripheral nervous system could expedite the regulatory approval process for its adaptation to Autonomix’s novel applications. This can be particularly advantageous in the highly regulated field of medical devices.
Addressing pancreatic cancer-related pain is a noteworthy focus area, given the current limitations of opioid-based treatments and invasive procedures. By leveraging a less invasive method, Autonomix could offer a safer alternative with potentially fewer side effects, enhancing the quality of life for patients. However, clinical success and validation through robust trials will be important for this technology to gain widespread acceptance among healthcare providers.
The potential for follow-on indications further highlights the device's versatility and market expansion capabilities, which could be promising for long-term growth.
From a market perspective, the acquisition of the Apex 6 Generator intellectual property is a strategic move for Autonomix. The device’s alignment with their existing system could create a competitive advantage in the medical device market, particularly in the pain management segment. The global market for pain management is substantial and a technologically advanced, less invasive solution could capture significant market share.
Additionally, the collaboration with RF Innovations and their involvement in the manufacturing process might ensure high-quality production standards and reliability, essential factors for gaining trust within the medical community. By addressing a specific unmet need in the realm of pancreatic cancer, Autonomix could position itself as a pioneering leader in innovative pain management solutions.
However, market penetration will heavily depend on successful commercialization and gaining endorsements from key opinion leaders and healthcare institutions. Investors should watch for early adoption rates and feedback from initial clinical deployments to gauge the technology’s reception and market potential.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development
Transaction further reinforces Autonomix’s FDA regulatory pathway
THE WOODLANDS, TX, July 15, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator. The Apex 6 Generator is an FDA-cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. The transaction is expected to close before the end of July 2024.
The transaction, for 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license of the Apex 6 Generator intellectual property. Autonomix plans to utilize the technology in its strategic therapeutic areas to drive value across its pipeline.
“This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management,” commented Brad Hauser, President and Chief Executive Officer of Autonomix. “I would like to commend our team for their hard work in identifying and validating this compatible radio frequency ablation generator that will be used in conjunction with our novel sensing device. Additionally, the team from RF Innovations is deeply experienced in the development and manufacturing of radio frequency generators and their assistance will be invaluable as we move our system forward towards commercialization. Together, we can work to adapt the technology for our specific use case and accelerate our journey to revolutionize how diseases involving the nervous system are diagnosed and treated.”
To facilitate equipment development, activities will begin immediately with RF Innovations manufacturing partner who will be incorporated into Autonomix’s manufacturing supply chain.
Autonomix is initially developing its technology to address pancreatic cancer-related pain, with plans for follow-on indications pending the results of the initial data. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects. For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without an effective solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward looking statements in this press release include, without limitation, the timing of the closing of the license transaction and ability of Autonomix to adapt the licensed technology for its specific use case. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” “can,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
FAQ
What is the purpose of Autonomix Medical's (AMIX) agreement with RF Innovations?
How much did Autonomix Medical (AMIX) pay for the RF Innovations license?
What is the primary focus of Autonomix Medical's (AMIX) technology development?
When is the transaction between Autonomix Medical (AMIX) and RF Innovations expected to close?
